A total of 779 patients with gastric cancer were screened (1/1/2004-12/31/2010)

A total of 573 cases were excluded due to other first-line chemotherapy (e.g., oxaliplatin, irinotecan, or TS-1) or synchronous cancers.

A total of 206 eligible cases were screened.

A total of 27 patients were lost to follow-up; 33 tissues were unavailable.

A total of 146 patients were selected.